Because both CD73 and CD39 play a major role (s) in modulation of the immune system and the tumor microenvironment as well as the tumor itself, we have developed an assay platform that monitors the activity of both of these enzymes in vitro (biochemically) and in cell-based assay formats. This evidence concerns the gene ENTPD1 and neoplasm.